v3.26.1
Segments (Tables)
 3 Months Ended
Mar. 31, 2026
Segment Reporting [Abstract]  
Schedule of Forth Disaggregated Research and Development Expenses

In addition to the significant expense categories included within net loss presented on the unaudited condensed consolidated statements of operations and comprehensive loss, the following table sets forth disaggregated research and development expenses (in thousands):

 

 

Three Months Ended March 31,

 

 

2026

 

 

2025

 

Direct research and development expenses:

 

 

 

 

 

 

Budoprutug

 

$

5,363

 

 

$

6,141

 

CLYM1161

 

 

1,193

 

 

 

9,120

 

Legacy programs2

 

 

22

 

 

 

299

 

Unallocated research and development expenses:

 

 

 

 

 

 

Personnel-related (including stock-based compensation)

 

 

2,353

 

 

 

1,757

 

Other research and development expenses

 

 

442

 

 

 

10

 

Total research and development expenses

 

$

9,373

 

 

$

17,327

 

 

1 Includes the upfront payment and the associated direct transaction costs incurred in connection with the Mabworks Agreement for the three months ended March 31, 2025.

2 Includes direct expenses related to the Company's legacy product candidates ETX-123 and ETX-155.